Atara Biotherapeutics Announces First Quarter 2023 Financial Results and Operational Progress
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Atara Biotherapeutics to Announce First Quarter 2023 Financial Results on Monday, May 8, 2023
Latest Financial Results
Latest Annual Filing
For Fiscal Year Ending Dec 31, 2022
Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. The company was founded in 2012, and since 2014 the company’s stock has been publicly traded on Nasdaq under the symbol ATRA.
Atara’s most advanced T-cell immunotherapy in development, tabelecleucel or tab-cel® (formerly known as ATA129), is being developed for the treatment of patients with Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorder (EBV+ PTLD), as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma (NPC).
Atara is also developing off-the-shelf, allogeneic ATA188 for the potential treatment of multiple sclerosis (MS).
Investor & Media Contacts
Chief Financial Officer
T: (805) 395-9669
Vice President, Corporate Communications & Public Affairs
T: (805) 456-4772
Computershare Trust Company, N.A.
P.O. Box 505000
Louisville, KY 40233
T: (781) 575-2879